Literature DB >> 3188617

NIH test, a problematic method for testing potency of inactivated rabies vaccine.

R Barth1, G Diderrich, E Weinmann.   

Abstract

A critical review of the NIH test is given. The results of four studies are presented which show that in the case of purified chick embryo cell inactivated rabies vaccine there is a profound difference between the result after heterologous intracerebral challenge with the prescribed CVS strain and homologous challenge with the LEP-C 26 strain. CVS strains from various laboratories produced relatively uniform results following intracerebral administration. Two in vitro tests, the single radial immunodiffusion test and the modified antibody binding test were employed in the studies. The results are discussed and alternative procedures to the NIH test are recommended for future consideration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3188617     DOI: 10.1016/0264-410x(88)90185-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.

Authors:  Sunil Gairola; Manish Gautam; Satish Waghmare
Journal:  Hum Vaccin Immunother       Date:  2020-01-23       Impact factor: 3.452

2.  Secretion of truncated recombinant rabies virus glycoprotein with preserved antigenic properties using a co-expression system in Hansenula polymorpha.

Authors:  Weidong Qian; Frank Aguilar; Ting Wang; Bingsheng Qiu
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

3.  A semi-quantitative serological method to assess the potency of inactivated rabies vaccine for veterinary use.

Authors:  Ye Liu; Shoufeng Zhang; Fei Zhang; Rongliang Hu
Journal:  Virol Sin       Date:  2012-07-28       Impact factor: 4.327

4.  An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines.

Authors:  Todd G Smith; James A Ellison; Xiaoyue Ma; Natalia Kuzmina; William C Carson; Charles E Rupprecht
Journal:  Vaccine       Date:  2013-06-03       Impact factor: 3.641

5.  Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo.

Authors:  Yulan Yan; Lijuan Jia; Jin Zhang; Yang Liu; Xuefeng Bu
Journal:  Oncol Lett       Date:  2014-09-25       Impact factor: 2.967

6.  A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.

Authors:  Guanfeng Lin; Shaolang Chen; Hui Zhao; Junyu Liang; Qiaoting Deng; Rongliang Liang; Xinxin Guo; Zhenhua Chen; Baihong Chen; Tiancai Liu; Yingsong Wu
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

7.  The adaptation of a CTN-1 rabies virus strain to high-titered growth in chick embryo cells for vaccine development.

Authors:  Caiping Guo; Chunhua Wang; Shan Luo; Shimao Zhu; Hui Li; Yongdi Liu; Lanzhen Zhou; Pei Zhang; Xin Zhang; Yujiang Ding; Weirong Huang; Kaiyong Wu; Yanpeng Zhang; Weihua Rong; Hua Tian
Journal:  Virol J       Date:  2014-05-12       Impact factor: 4.099

8.  Non-animal replacement methods for veterinary vaccine potency testing: state of the science and future directions.

Authors:  Jodie Kulpa-Eddy; Geetha Srinivas; Marlies Halder; Richard Hill; Karen Brown; James Roth; Hans Draayer; Jeffrey Galvin; Ivo Claassen; Glen Gifford; Ralph Woodland; Vivian Doelling; Brett Jones; William S Stokes
Journal:  Procedia Vaccinol       Date:  2011-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.